H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes BBP-418 in its valuation assessment with an 80% probability of approval. BridgeBio reported “highly favorable and clinically meaningful” top-line interim data from the Phase 3 FORTIFY trial of BBP-418 in patients with limb girdle muscular dystrophy, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Announces Positive Phase 3 Study Results
- BridgeBio Pharma’s Promising Phase 3 Results and Accelerated Approval Path Justify Buy Rating
- BridgeBio price target raised to $69 from $59 at Raymond James
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- BridgeBio reports results from FORTIFY Phase 3 study of BBP-418